Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.
Diabetes and endocrinology · Diabetes Care · 2026-11-01
RCTn = 102
Liu et al. Calorie-Restricted DASH, Carbohydrate-Restricted, and Low-Purine Diets for Weight Loss and Urate Control in Men With Overweight or Obesity and Hyperuricemia: A Randomized TrialDiabetes and endocrinology · N Engl J Med · 2026-09-29
RCTn = 2,339
Jastreboff et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of ObesityDiabetes and endocrinology · Lancet · 2026-09-29
RCTn = 1,152
Bellido et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trialDiabetes and endocrinology · Lancet Diabetes Endocrinol · 2026-09-29
RCTn = 493
Garvey et al. Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trialDiabetes and endocrinology · Lancet Diabetes Endocrinol · 2026-08-21
RCTn = 179
Hsia et al. Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial